SHAREHOLDER ALERT: L & K Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Spe...

Levi & Korsinsky, LLP announces that it has commenced an investigation of Spectrum Pharmaceuticals, Inc. (“Spectrum Pharmaceuticals” or the “Company”) (NASDAQGS: SPPI) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

On October 23, 2015, Spectrum announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application seeking clearance for Evomela, indicating that the FDA cannot approve the application in its present form. Upon this news, shares of Spectrum Pharmaceuticals fell more than 20% on intraday trading. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/spectrum

or contact Joseph E. Levi, Esq. either via email at [e-mail] or by telephone at [phone], toll-free: [phone].

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151023005883/en/

Levi & Korsinsky, LLPJoseph E. Levi, Esq.Tel: [phone]Toll Free: 877-363-5972Fax: [phone]www.zlk.com